RXi Pharmaceuticals Names Life Science Veteran Stephen J. DiPalma Chief Financial Officer.WORCESTER, Mass. -- RXi Pharmaceuticals Corporation, a subsidiary of Cytrx Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CYTR CYTR Canadian Yorkshire Terrier Rescue CYTR Constant Yield Tax Rate (property tax) ), today announced the appointment of Stephen J. DiPalma as Chief Financial Officer. The Company also announced the planned departure of James Warren to pursue other opportunities. "We welcome Steve DiPalma to the RXi management team. Steve is an accomplished veteran who brings over 20 years of financial, operations and business development experience in early-stage life science companies, including broad financial and strategic management in both private and public companies. We intend to call upon his significant expertise to assist RXi in reaching our corporate goal of developing and commercializing proprietary RNAi therapeutics," said Tod Woolf, Ph.D., RXi's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "I would like to thank Jim Warren for his valuable contributions to RXi during our formation period, first as a consultant and later as Chief Financial Officer." Most recently, Mr. DiPalma was co-founder, President and Chief Executive Officer of Catalyst Oncology, Inc., a company providing cost-effective personalized medicine solutions to the oncology market, which was recently merged with a public diagnostics company. Prior to Catalyst, he served as Chief Financial Officer at Milkhaus Laboratory, a clinical stage drug development company, where he was instrumental in business development, strategic planning, finance and accounting, with a focus on capital strategies. He also served as Chief Financial Officer at Phytera, Inc., an international biopharmaceutical company. Mr. DiPalma's past accomplishments include the successful turnaround of publicly traded Aquila Biopharmaceuticals while serving as Chief Financial Officer. Additionally, he co-founded and served as Chief Financial Officer of Athena Diagnostics, Inc., a premier specialty reference laboratory providing innovative tests for neurological disorders. Mr. DiPalma holds an M.B.A. from Babson College and a B.S. in business administration from the University of Massachusetts The system includes UMass Amherst, UMass Boston, UMass Dartmouth (affiliated with Cape Cod Community College), UMass Lowell, and the UMass Medical School. It also has an online school called UMassOnline. at Lowell. He is a member of the Financial Executives Institute, Financial Executives Networking Group, Association for Corporate Growth and the National Investor Relations Institute The National Investor Relations Institute, known as "NIRI", is the professional association for investor relations professionals in the United States. NIRI was founded in 1969 and has more than 4,500 members, both from the United States and other countries. . About RXi Pharmaceuticals Corporation Massachusetts-based RXi Pharmaceuticals Corporation is a biopharmaceutical research and development company that focuses on developing RNAi-based therapeutics for the treatment of human disease. RXi's initial focus is on neurodegenerative diseases neurodegenerative diseases diseases characterized by neurodegeneration. Lesions are microscopic only but in chronic disease with massive involvement there may be grossly visible atrophy of affected nervous tissue. , oncology, type 2 diabetes type 2 diabetes n. See diabetes mellitus. and obesity. RXi has licenses to a diverse series of early patents and patent applications that were filed from 1998 to 2006 in the areas of RNAi target sequences, RNAi chemistry and RNAi delivery. The Company was founded by RNAi pioneers Craig Mello, Ph.D., 2006 Nobel Laureate for co-discovering RNAi and co-inventing RNAi therapeutics; Tariq M. Rana, Ph.D., inventor of fundamental technology for stabilizing RNAi and of RNAi nanotransporters; Greg Hannon, Ph.D., discoverer of RNAi mechanism (RISC RISC in full Reduced Instruction Set Computing Computer architecture that uses a limited number of instructions. RISC became popular in microprocessors in the 1980s. ) and short hairpin hairpin a secondary structure that occurs in single-strand RNA during protein synthesis in which the strand turns back on itself. The structure is the result of base pairing and hydrogen bond formation. RNAi (shRNA); and Michael Czech, Ph.D., a leader in the application of RNAi to diabetes and obesity. RXi's CEO, Tod Woolf, Ph.D., previously co-invented and commercialized STEALTH[TM] RNAi, one of the most widely used second-generation RNAi research products. The Company currently operates as a privately held subsidiary of CytRx Corporation (NASDAQ: CYTR) and is located in Worcester, MA. Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and any current reports on Form 8-K Form 8-K The form required by the SEC when a publicly held company incurs any event that might affect its financial situation or the share value of its stock. Form 8-K See 8-K. filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion